In our experience, we believe that this full healthcare access is crucial to minimize the difference in outcomes, similar to findings in a universal healthcare (8, 20), or single payer systems (10) due to appropriate prostate cancer screening with PSA, access to imaging exams such as Multiparametric Resonance Image (MRI), and follow-up according to established guidelines. This evidence concerns the gene KLK3 and prostate cancer.